S&P/ASX 200 Index (ASX: XJO) shares are down 0.2% to 9,060.3 points on Monday.
Let's start the new week with some fresh ratings from the experts (courtesy The Bull).

Image source: Getty Images
Coles Group Ltd (ASX: COL)
The Coles share price is $22.22, down 0.1% today and down 0.5% over 12 months.
Andrew Wielandt from DP Wealth Advisory has a buy rating on this ASX 200 consumer staples share.
Wielandt considers Coles a "defensive, cash-generating business" trading at an attractive share price following a recent sell-off.
The Coles share price fell by almost 10% after the company forecast flat earnings for the first half due to higher fuel-related costs.
He said:
The supermarkets business continues to grow.
Supermarket sales of $10.320 billion in the first quarter of 2027 rose 3.6 per cent on the prior corresponding period.
eCommerce sales jumped 22.9 per cent, lifting online penetration to 15.7 per cent.
We believe the sell-off has been overdone. Coles offers longer term investors an attractive entry point.
Wesfarmers Ltd (ASX: WES)
The Wesfarmers share price is $80.36, down 0.6% today and down 0.6% over 12 months.
Wielandt has a hold recommendation on this ASX 200 consumer discretionary share given the current cost-of-living crisis.
Wesfarmers owns retailers Bunnings, Beaumont Tiles, Kmart, Priceline, and Officeworks.
Hardware giant Bunnings is its biggest earner, and management spoke of moderating sales growth since 2H FY26 at the AGM.
He said:
Wesfarmers is a quality business.
However, consumer spending remains under pressure, so we retain a hold recommendation until the interest rate cycle appears close to peaking.
We hold WES in our DP wealth model SMA portfolios.
CSL Ltd (ASX: CSL)
The CSL share price is $202.29, down 0.3% today and up 12% over 12 months.
Steven Springford from Catapult Wealth gives this ASX 200 healthcare share a sell rating.
CSL hit a nine-year low of $90 per share in May. Its rebound has been nothing short of remarkable, rising 125% over five months.
Springford says the market has been disappointed in CSL's business performance, but noted that management expects a 5% profit lift in FY27.
Despite that, CSL's strong share price recovery makes him wary of the company's valuation right now.
Springford said:
… given the steep share price rise in a relatively short period, much of the expected improvement is likely to be factored into the stock, leaving limited prospective growth in the near future.
Investors may want to consider cashing in some gains at these levels to guard against any potential correction.